1. Introduction
===============

Retinal vein occlusion (RVO) is a prevalent vision-threatening disease,^\[[@R1],[@R2]\]^ which is the second largest retinal vascular disease leading to blindness safter diabetic retinopathy.^\[[@R3]\]^ RVOs are classified based on the site of the occlusion as branch retinal vein occlusion (BRVO), central retinal vein occlusion (CRVO), and hemiretinal vein occlusion. And also it can be further divided into ischemic and non-ischemic types. Macular edema (ME) is a common complication and a primary cause of vision loss in all forms of RVO.^\[[@R4],[@R5]\]^ Early treatment of ME associated with RVO is with better long-term visual outcomes.^\[[@R6],[@R7]\]^

The formation of ME secondary to RVO is mainly due to increased secretion of vascular endothelial growth factor (VEGF). VEGF is an important factor that stimulates the formation of new blood vessels in the choroid and retina.^\[[@R8]\]^ It leads to increased vascular permeability and angiogenesis, aggravating retinal ischemia, and hypoxia.^\[[@R9]\]^ This further aggravate the ME. Anti-VEGF treatment has become the main treatment method for ME secondary to RVO.

At present, anti-VEGF drugs have been widely used with definite clinical efficacy, such as.^\[[@R10]\]^ But there exist many problems. The effects are not long-lasting, requiring repeated injections. And the drugs are expensive and may cause a variety of complications. It is of great significance to find a safer and more effective treatment for ME associated with RVO.

Artemisinin is a sesquiterpenoid lactolide compound containing peroxide group extracted from artemisia annua by Chinese scientists.^\[[@R11]\]^ It not only can resist malaria, but also parasite and tumor, and affect the immune system function and inhibit vascular hyperplasia. Therefore, it is necessary to evaluate the efficacy of artemisinin in the treatment of ME associated with RVO.

2. Outcomes
===========

The primary outcomes of this review are visual acuity (VA) and central retinal thickness (CRT). The second outcomes are parameters on optical coherence tomography angiography (OCTA) including the following items: superficial capillary plexus (SCP), deep capillary plexus (DCP), vessel density (VD), foveal avascular zone (FAZ).

3. Materials and methods
========================

3.1. Study registration
-----------------------

This study will follow the guidelines outlined in the preferred reporting items for systematic reviews and meta-analysis (PRISMA) statement for meta-analyses of healthcare interventions.^\[[@R12]\]^ Additionally, the protocol adheres to the PRISMA Protocols (PRISMA-P).^\[[@R13]\]^ The selection process will be summarized according to PRISMA flow diagram (Fig. [1](#F1){ref-type="fig"}).

![Flow diagram of studies search and selection.](medi-98-e16044-g001){#F1}

The protocol for this systematic review has been registered on PROSPERO under the number CRD42019131408.

3.2. Types of studies
---------------------

Randomized controlled trials (RCTs) regarding intervention of artemisinin in ME associated with RVO will be included without restriction language.

3.3. Types of participants
--------------------------

Patients were histologically confirmed of RVO.

3.4. Types of interventions
---------------------------

Intervention: artemisinin therapy. Comparator: anti-VEGF drugs.

4. Search methods for the identification of studies
===================================================

The Cochrane Library, MEDLINE, Embase, Chinese BioMedical Database (CBM), China National Knowledge Infrastructure (CNKI), Chinese VIP Information (VIP), Wangfang Database will be searched regardless of publication date, or language.

5. Data collection and analysis
===============================

5.1. Selection of studies and data extraction
---------------------------------------------

Two reviewers will extract data independently from the eligible studies by using a standardized collection form. We will record the details of the eligible studies including: first author, publication time, study design, comparator, study period, numbers of outcomes, sex, age, type, histologic diagnosis, clinical pathological features, and outcomes. If above-mentioned information is not able to get, we will contact the corresponding author for detailed data. If there are discrepancies between the 2 reviewers, a final consensus will be resolved through discussion with the third researcher.

5.2. Assessment of risk of bias in included studies
---------------------------------------------------

We will use Cochrane Collaboration tool to assess the risk of bias.^\[[@R14]\]^ Each included study will be evaluated respectively by 2 researchers. Random sequence generation, allocation concealment, subjects and researchers blinded, outcome evaluation of blind method, the result data are incomplete and selective report results and other issues are involved and classified as "low," "high," or "unclear" based on Cochrane Collaboration tool. If there are divided opinions between 2 researchers in procession, we will resolve inconsistencies through discussion or asking for a help from a senior researcher.

5.3. Measures of treatment effect
---------------------------------

We will apply relative risk (RR) to represent the enumeration data; measurement data will be represented by mean difference (MD) and 95% confidence interval (95% CI).

5.4. Dealing with missing data
------------------------------

Corresponding authors will be connected by E-mail for detailed data if their studies' information is not available. If no additional message is received, we will conduct data synthesis using available data.

5.5. Assessment of quality in included studies
----------------------------------------------

The quality of each selected studies will be evaluated using the Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach by 3 investigators.

5.6. Assessment of heterogeneity
--------------------------------

Random models will be applied to conduct the meta-analysis. We will use chi-squared-based *Q* test and *I*^2^ test to evaluate the heterogeneity of all studies included. And *P* \< .10 or *I*^2^ values \>50 means high heterogeneity among studies included.^\[[@R14]\]^ If there is a high heterogeneity, we will conduct subgroup analyses to explore the possible causes.

5.7. Assessment of reporting bias
---------------------------------

If there are \>10 included trials in this review, funnel plot will be used to discuss the reporting biases or small-study effects according Egger methods and Begger^\[[@R15]\]^ test with *P* \< .05 indicating significant bias and a contribution of heterogeneity.

5.8. Data synthesis
-------------------

We will use RevMan 5.3.5 software (The Cochrane Collaboration, Oxford, England, UK) and STATA 14 software (version 14.0; Stata Corp, College Station, TX) to calculate for data synthesis. If there no obvious statistical heterogeneity among the trails included, we will apply fixed effects model to perform in the analysis. However, the random effects model will be used, when apparent clinical heterogeneity among the trails included. Meanwhile, subgroup or sensitivity analysis will be conducted. *α* = 0.05 will be deemed statistically significant.

5.9. Subgroup analysis
----------------------

Subgroup analysis will be conducted according to sex, histologic diagnosis, duration of artemisinin therapies, and anti-VEGF drugs.

5.10. Sensitivity analysis
--------------------------

Sensitivity analysis will be conducted to explore the quality of studies of the document following sample size, the outcome of missing data, and methodological quality.

5.11. Ethics and dissemination
------------------------------

Ethical approval is not required because individual patient information will be not used. The authors will disseminate this systematic review through conference presentations and peer-review publications.

6. Discussion
=============

Expanding clinical applications of artimisinin is of interest to public health.^\[[@R16]\]^ Although, few studies have been reported to show the efficiency of artimisinin in the treatment of ME associated with RVO. With the further development of artemisinin research, there are more and more studies in this field. A systematic review which can provide the newest data should be conducted to show such therapeutic method associated with better VA and other examination results. Therefore, this protocol for a systematic review has to be displayed. We hope that our works will help clinicians with more convincing evidence about dealing with patients with ME secondary to RVO.

However, this review still has some limitations. Due to language barriers, only studies published in Chinese and English will be included. Besides, different countries and histology type of RVO may run risk of heterogeneity.
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